GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Operating Margin %

Shanghai Junshi Biosciences Co (HKSE:01877) Operating Margin % : -83.66% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Shanghai Junshi Biosciences Co's Operating Income for the three months ended in Mar. 2024 was HK$-346.1 Mil. Shanghai Junshi Biosciences Co's Revenue for the three months ended in Mar. 2024 was HK$413.7 Mil. Therefore, Shanghai Junshi Biosciences Co's Operating Margin % for the quarter that ended in Mar. 2024 was -83.66%.

Good Sign:

Shanghai Junshi Biosciences Co Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's Operating Margin % or its related term are showing as below:

HKSE:01877' s Operating Margin % Range Over the Past 10 Years
Min: -72590.95   Med: -175.04   Max: -14.73
Current: -890.78


HKSE:01877's Operating Margin % is ranked worse than
71.1% of 1031 companies
in the Biotechnology industry
Industry Median: -169.17 vs HKSE:01877: -890.78

Shanghai Junshi Biosciences Co's 5-Year Average Operating Margin % Growth Rate was 58.20% per year.

Shanghai Junshi Biosciences Co's Operating Income for the three months ended in Mar. 2024 was HK$-346.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1,324.6 Mil.

Warning Sign:

Shanghai Junshi Biosciences Co Ltd had lost money in 50% of the time over the past 12quarters.


Shanghai Junshi Biosciences Co Operating Margin % Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Operating Margin % Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -98.97 -104.61 -14.73 -186.88 -163.19

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -238.13 -129.72 54.33 - -83.66

Competitive Comparison of Shanghai Junshi Biosciences Co's Operating Margin %

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Operating Margin % falls into.



Shanghai Junshi Biosciences Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Shanghai Junshi Biosciences Co's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-2681.963 / 1643.457
=-163.19 %

Shanghai Junshi Biosciences Co's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-346.066 / 413.668
=-83.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Shanghai Junshi Biosciences Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines